The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Workforce
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / The ACR’s State-of-the-Art Clinical Symposium: Experts Discuss Jakinibs, Osteoarthritis, Membranous Lupus Nephritis

The ACR’s State-of-the-Art Clinical Symposium: Experts Discuss Jakinibs, Osteoarthritis, Membranous Lupus Nephritis

July 14, 2015 • By Thomas R. Collins

  • Tweet
  • Email
Print-Friendly Version / Save PDF
best pixels/shutterstock

Image Credit: best pixels/shutterstock

CHICAGO—With the approval of the Jak inhibitors (i.e., jakinibs) tofacitinib and ruxolitinib—and others being investigated—rheumatologists need to arm themselves with an understanding of these drugs so they can think critically when evaluating them and deciding how to use them, said John O’Shea, MD, chief of the Molecular Immunology and Inflammation Branch of and scientific director for intramural research at the National Institute of Arthritis and Musculoskeletal and Skin Diseases.

You Might Also Like
  • ACR 2013 State-of-the-Art Clinical Symposium: What’s Next in Therapy for Osteoarthritis, Rheumatoid Arthritis, and Lupus?
  • The ACR’s State-of-the-Art Clinical Symposium: Stem Cell Therapy in Autoimmune Disease Evolution, Insights
  • ACR State-of-the-Art Clinical Symposium
Explore This Issue
July 2015
Also By This Author
  • Tech Talk: Physicians Debate Using Cell Phones to Communicate with Patients

Dr. O’Shea—a foremost expert on “Jaks,” or Janus kinases, who helped develop tofacitinib—spoke at the American College of Rheumatology’s 2015 State-of-the-Art Clinical Symposium in May, highlighting the history of Jak development and questions that have yet to be answered as the field moves forward.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

His talk led off a session on The Big Three, which also included talks on osteoarthritis and the impact footwear can have on knee inflammation; and membranous glomerulonephritis treatment in systemic lupus erythematosus.

Jakinibs

Jaks—four of 518 protein kinases—are phosphotransferases that bring about the transfer of ATP to cytokine receptors, which allows cell signaling molecules, such as STAT proteins, to be recruited. Jak inhibitors block this ATP binding and prevent receptors from transmitting signals.

Dr. O’Shea

Dr. O’Shea

Approved jakinibs—ruxolitinib, which targets Jak1 and Jak2, and is approved for polycythemia and myelofibrosis; and tofactinib, which targets Jak1 and Jak3, and is approved for RA—will likely soon be joined by others. Drugs that target Jak1, along with others, are in development.

“Jakinibs are a reality—many more to come,” Dr. O’Shea said.

Dr. O’Shea said that it’s important to understand that when a drug inhibits the Jak/STAT pathway, multiple cytokines are being inhibited, and the clinical upshot of that scope of inhibition is not yet known. He said it isn’t clear yet whether this multiple-cytokine inhibition is the reason why toficitinib and baracitinib work. And, if a second generation of Jak inhibitors is more selective, he said, it isn’t known whether they will work as well or have a better safety profile.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

“The things you should be asking yourself as you’re looking at posters at the ACR [Annual Meeting] are which Jak is being inhibited? What other kinases are being inhibited? The scientific question[s] really [are], ‘What is the basis of efficacy? Which cytokines? Which ones are really important in which cells?’”

Dr. O’Shea said that when jakinibs were first being developed, the prevailing idea was that a drug that blocks ATP would have “this exquisite specificity.” But it turns out that the 20 or so approved kinase inhibitors have varying levels of specificity.

Pages: 1 2 3 4 5 | Single Page

Filed Under: Conditions, Drug Updates, Education & Training, Meeting Reports, Professional Topics, SLE (Lupus) Tagged With: AC&R, clinical symposium, JAK inhibitor, Lupus, Osteoarthritis, outcome, patient care, Research, TreatmentIssue: July 2015

You Might Also Like:
  • ACR 2013 State-of-the-Art Clinical Symposium: What’s Next in Therapy for Osteoarthritis, Rheumatoid Arthritis, and Lupus?
  • The ACR’s State-of-the-Art Clinical Symposium: Stem Cell Therapy in Autoimmune Disease Evolution, Insights
  • ACR State-of-the-Art Clinical Symposium
  • The ACR’s State-of-the-Art Clinical Symposium: Patients with Scleroderma, Lung Disease May Benefit from Aggressive Therapy

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.